Because EGFR TKI, especially erlotinib (Tarceva) is indicated for the second‐line treatment or beyond after the failure of previous chemotherapy for NSCLC (not limited to adenocarcinoma).23, 24. The gene discussed is EGFR; the disease is adenocarcinoma.